Systemic targeting inhibitor of κB kinase inhibits melanoma tumor growth

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3127-3134

  Yang, Jinming ^a   Pan, Wei Hua ^b   Clawson, Gary A ^b   Richmond, Ann ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; HAMMERHEAD RIBOZYME; I KAPPA B KINASE; RIBOZYME;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; IN VIVO STUDY; MELANOCYTE; MELANOMA; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL GROWTH; CELL TRANSFORMATION; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BASE SEQUENCE; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, RAS; I-KAPPA B KINASE; MELANOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; RNA, CATALYTIC;

EID: 34248178207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3547     Document Type: Article

References (44)

1. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 Suppl:S81-96.
2. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
4. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004;431:405-6.
5. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
6. Gomperts BN, Strieter RM. Chemokine-directed metastasis. Contrib Microbiol 2006;13:170-90.
7. Yang J, Richmond A. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res 2001;61:4901-9.
8. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
9. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin Cancer Res 2006; 12:950-60.
10. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
11. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 2006;103: 10544-51.
12. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
13. Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 2001;276:41424-34.
14. Becker TM, Rizos H, de la Pena A, et al. Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun 2005;332:873-9.
15. Gu L, Zhu N, Findley HW, Woods WG, Zhou M. Identification and characterization of the IKKα promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem 2004;279:52141-9.
16. Yang J, Luan J, Yu Y, et al. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res 2001;61:8150-7.
17. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and Ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-34.
18. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400: 468-72.
19. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997;278:860-6.
20. Meier F, Schittek B, Busch S, et al. The RAS/RAF/ MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001.
21. Hess AR, Hendrix MJ. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006;5:478-80.
22. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5: 875-85.
23. Pan WH, Devlin HF, Kelley C, Isom HC, Clawson GA. A selection system for identifying accessible sites in target RNAs. RNA 2001;7:610-21.
24. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 1984;81:3806-10.
25. Kashani-Sabet M, Liu Y, Fong S, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci U S A 2002;99:3878-83.
26. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 2001;276:47828-33.
27. Ravi R, Bedi A. NF-κB in cancer - a friend turned foe. Drug Resist Updat 2004;7:53-67.
28. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target. J Cell Biochem 2004;92:646-50.
29. Ueda Y, Richmond A. NF-κB activation in melanoma Pigment Cell Res 2006;19:112-24.
30. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999;284:316-20.
31. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999;284:321-5.
32. Stein CA. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 2001;108:641-4.
33. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64: 2338-42.
34. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
35. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
36. Hanson JL, Hawke NA, Kashatus D, Baldwin AS. The nuclear factor κB sub-units RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res 2004;64:7248-55.
37. Dajee M, Lazarov M, Zhang JY, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-43.
38. Zhang JY, Green CL, Tao S, Khavari PA. NF-κB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev 2004;18:17-22.
39. Baumgartner B, Weber M, Quirling M, et al. Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts. Leukemia 2002;16:2062-71.
40. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
41. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13: 738-47.
42. Strieter RM. Mastering innate immunity. Nat Med 2003;9:512-3.
43. Pan WH, Xin P, Morrey JD, Clawson GA. A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol Ther 2004;9:596-606.
44. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.